Document is current
Any future updates will be listed below
-
Authors
Barchuk, Anton
Bulina, Anna
Cherkashin, Mikhail
Berezina, Natalia
Rakova, Tatyana
Kuplevatskaya, Darya
Skougarevskiy, Dmitriy
Okhotin, Artemiy
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct0498140 at ClinicalTrials.govDocuments that mention this clinical trial
Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study
https://doi.org/10.1186/s12931-022-02206-3
- License Information
-
More Information
Article History
Received: 30 May 2022
Accepted: 2 October 2022
First Online: 10 October 2022
Declarations
:
: The Ethics Committee of the MIBS approved the study on June 21, 2021. The Ethics Committee of the Pavlov First Saint Petersburg State Medical University approved the joint study of COVID-19 vaccine effectiveness in St. Petersburg on July 15, 2021. All research was performed following the relevant guidelines and regulations. All participants signed the informed consent upon referral to the LDCT triage. The joint study of COVID-19 vaccine effectiveness in St. Petersburg was registered at ClinicalTrials.gov (NCT04981405, date of registration—August 4, 2021). This publication covers the data collected at the two outpatient centres of the MIBS that contributed to the study data.
: Not applicable.
: Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Other authors have no competing interest or competing interests to declare.
: No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for the design or implementation of the study. No patients were asked to advise on the conduct, reporting, or dissemination plans of our research.
